News Sentiment

SVRA sentiment intelligence

Savara Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 48 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.52 Week of 17 Jul 2026
Weighted tone 48/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-8.5% over one week, +0.4% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -8.5% Price reacting lower
Trend fit Trend inactive 0.4% over four weeks
Fair value 34.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 43
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
TradingView 9
Stock Titan 9
The National Law Review 6
simplywall.st 4
TradingKey 4
Business Wire 3
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 16
Regulatory and legal 7
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
The National Law Review Direct company coverage

Join Class Action to Recover Losses from Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025

Levi & Korsinsky LLP has filed a class action securities lawsuit against Savara Inc. (SVRA) on behalf of shareholders who suffered losses due to alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements and concealed issues

Tone
Negative 18/100
Event
Regulatory and legal
Published
14 Jul 2026 17:42
Source
The National Law Review
AD HOC NEWS Direct company coverage

Savara stock. Thin-source profile holds the focus.

Savara Inc. (SVRA) continues to focus on its rare-disease pipeline and Nasdaq listing, with its lead program being molgramostim inhalation therapy for autoimmune pulmonary alveolar proteinosis. Despite the absence of new market catalysts, the company's development pipeline and fi

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 16:32
Source
AD HOC NEWS
TradingView Direct company coverage

Price to earnings forward of Savara, Inc. – NASDAQ:SVRA

This article displays the "Price to earnings forward" value for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the period value and change are displayed, and states that the information is "Made by humans."

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 10:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA

This article provides a financial snapshot for Savara, Inc. (NASDAQ: SVRA), focusing on its enterprise value to EBIT forward. It indicates whether there have been changes in this period and by what percentage. The data is supported by various financial services and is presented v

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 23:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA

This article displays the Enterprise Value to EBITDA forward for Savara, Inc. (NASDAQ: SVRA) on TradingView. It indicates that the market was closed at the time of viewing, with no trades reported. The content is primarily a data point without further analytical text.

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 05:11
Source
TradingView
Ad-hoc-news.de Direct company coverage

Savara Inc focuses on respiratory drug development as investors watch clinical progress

Savara Inc. is a clinical-stage biopharmaceutical company specializing in developing inhaled therapies for rare respiratory diseases. The company's strategy involves focusing on conditions with high unmet medical needs, pursuing orphan-drug designations, and advancing its pipelin

Tone
Positive 70/100
Event
Market update
Published
03 Jul 2026 18:09
Source
Ad-hoc-news.de
TradingView Direct company coverage

Price to book forward of Savara, Inc. – NASDAQ:SVRA

This article provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a section of a larger financial data display, indicating the period and value of this metric. It originates f

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 11:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Savara, Inc. – NASDAQ:SVRA

This page provides financial information for Savara, Inc. (NASDAQ: SVRA), specifically focusing on its price-to-sales forward metric. It appears to be a financial data snippet from TradingView, offering a quick overview of this particular financial ratio for the company.

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 06:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA

The article focuses on the enterprise value to revenue forward metric for Savara, Inc. (NASDAQ: SVRA). It appears to be a stub or a placeholder, as no specific financial data or analysis is presented in the provided content, only the title and navigation elements.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 13:41
Source
TradingView
The National Law Review Direct company coverage

Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline

Levi & Korsinsky LLP has announced a class action lawsuit against Savara Inc. (NASDAQ:SVRA), reminding investors of the November 7, 2025 deadline to join. The lawsuit alleges that Savara made false and misleading statements between March 4, 2024, and May 23, 2025, regarding the r

Tone
Negative 28/100
Event
Regulatory and legal
Published
30 Jun 2026 06:39
Source
The National Law Review
The National Law Review Direct company coverage

Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025

Levi & Korsinsky has announced a class action securities lawsuit against Savara Inc. (SVRA), urging investors who suffered losses between March 4, 2024, and May 23, 2025, to come forward by the lead plaintiff deadline of November 7, 2025. The lawsuit alleges that Savara made fals

Tone
Negative 18/100
Event
Regulatory and legal
Published
28 Jun 2026 19:39
Source
The National Law Review
The National Law Review Direct company coverage

Securities Lawsuit Alert: Savara Inc. (SVRA) Investors - Contact Levi & Korsinsky Before November 7, 2025

Levi & Korsinsky LLP has announced a securities lawsuit alert for investors of Savara Inc. (NASDAQ:SVRA). The class action seeks to recover losses for shareholders affected by alleged securities fraud between March 4, 2024, and May 23, 2025, primarily concerning misstatements abo

Tone
Negative 18/100
Event
Regulatory and legal
Published
28 Jun 2026 18:10
Source
The National Law Review
The National Law Review Direct company coverage

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline

Levi & Korsinsky LLP has issued a class action lawsuit alert for investors of Savara Inc. (NASDAQ: SVRA). The lawsuit, filed on behalf of shareholders who experienced losses between March 4, 2024, and May 23, 2025, alleges the company made false statements regarding its MOLBREEVI

Tone
Negative 30/100
Event
Regulatory and legal
Published
28 Jun 2026 17:10
Source
The National Law Review
The National Law Review Direct company coverage

Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025

Levi & Korsinsky LLP has announced a class action securities lawsuit against Savara Inc. (SVRA) for alleged securities fraud between March 4, 2024, and May 23, 2025. The lawsuit claims Savara made false statements regarding its MOLBREEVI BLA treatment, suggesting insufficient che

Tone
Negative 28/100
Event
Regulatory and legal
Published
28 Jun 2026 13:09
Source
The National Law Review
TradingView Direct company coverage

SVRA Forecast — Price Target — Prediction for 2027

This article provides a forecast and price target for Savara, Inc. (SVRA) stock, based on analyst ratings and historical performance. It details current and historical stock prices, market capitalization, volatility, and future earnings estimates. The article also includes a Q&A

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 06:09
Source
TradingView
TradingView Direct company coverage

Savara, Inc. Actuals & Estimates (FWB:YB4P)

This article provides an overview of Savara, Inc. (FWB: YB4P) including financial actuals and estimates, stock forecasts, and frequently asked questions. It details analyst price targets, historical stock performance, upcoming earnings dates, recent earnings per share, and revenu

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:40
Source
TradingView
Kavout | AI Direct company coverage

What Does the FDA's Priority Review Mean for Savara's MOLBREEVI

Savara Inc. achieved a significant milestone with the FDA’s Priority Review for its Biologics License Application (BLA) for MOLBREEVI, setting an August 22, 2026, PDUFA date. MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis (aPAP), addresses a rare lung disease with

Tone
Positive 73/100
Event
Market update
Published
26 Jun 2026 05:09
Source
Kavout | AI
TradingView Direct company coverage

YB4P Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Savara, Inc. (YB4P) stock on the Frankfurt Stock Exchange. It includes analyst ratings, estimated future prices, historical stock performance, and key financial data such as earnings per share and revenue. The report also addre

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 02:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Savara Inc For: 22 June By Investing.com

This article from Investing.com reports that Savara Inc. filed a Form 4 for insider transactions on June 22. The brief notice includes the stock symbol SVRA, which showed a 1.58% increase. The article provides minimal detail beyond the filing reference.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 01:34
Source
Investing.com Nigeria
Investing.com Nigeria Direct company coverage

Savara CFO David Lowrance sells $2.24m in company stock By Investing.com

Savara CFO David Lowrance sold 394,528 shares of the company's common stock for approximately $2.24 million and acquired 580,187 shares through stock options for about $1.02 million. Following these transactions, including share dispositions for tax liabilities, Lowrance directly

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4

Savara Inc.'s CFO, David L. Lowrance, exercised 580,187 stock options and sold 394,528 shares of common stock in an open-market transaction on June 22, 2026, at a weighted average price of $5.6813 per share. Additionally, 185,659 shares were withheld to cover tax obligations. Fol

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 00:10
Source
Stock Titan
Stock Titan Direct company coverage

[144] Savara Inc SEC Filing

This SEC filing for Savara Inc. (SVRA) is a Form 144, indicating a notice of proposed sale of securities under Rule 144. The filing details the sale of 394,528 common shares with an aggregate market value of $2,229,000.00, through Raymond James & Associates on June 22, 2026, obta

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 19:10
Source
Stock Titan
Simply Wall Street Direct company coverage

Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)?

Savara Inc. recently gained stockholder approval to double its authorized common shares to 600,000,000 and announced that CFO Dave Lowrance would depart due to health reasons, with COO Robert Lutz assuming the CFO role. These changes introduce capital flexibility and leadership c

Tone
Negative 35/100
Event
Regulatory and legal
Published
20 Jun 2026 19:39
Source
Simply Wall Street
TradingKey Direct company coverage

Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 207 out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -9.49, which is significantly below its recent high and above it

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of June 16, 2026, SVRA has a price momentum score of 8.99 and is trading between a resistance level of 5.65 and a

Tone
Positive 62/100
Event
Market update
Published
17 Jun 2026 02:10
Source
TradingKey